,Regulatory Affairs Certification (RAC)
Advanced Prep: Master Global & US
Regulatory Pathways & Compliance Practice
Questions
Subject: Healthcare Product Lifecycle & Global Regulatory Affairs
Question 1: A medical device manufacturer is preparing a 510(k) submission for a new
cardiovascular stent. Which of the following conditions, if present, would most likely lead to the
FDA determining that the device is "not substantially equivalent" (NSE)?
A) The device utilizes a new biocompatible coating never before used on an FDA-cleared stent.
B) The device is similar in intended use but uses a different sterilization method than the
predicate.
C) The device has a slightly different geometric profile that does not impact its performance
characteristics.
D) The clinical data provided shows the device performs identically to the predicate device.
Correct Answer: A) The device utilizes a new biocompatible coating never before used on an
FDA-cleared stent.
*Explanation: The 510(k) pathway is predicated on demonstrating substantial equivalence to a
legally marketed predicate device. While minor modifications in labeling or materials are often
acceptable, the introduction of a new technology—such as a novel biocompatible coating—
introduces new questions of safety and effectiveness that cannot be adequately addressed
through a 510(k) comparison, necessitating a Premarket Approval (PMA) or a De Novo
classification request. Distractors B and C describe modifications that are often manageable
within a 510(k) framework via supplemental performance data, and D describes a scenario that
strongly supports substantial equivalence.
Question 2: Under the 21 CFR 812 regulations for Investigational Device Exemptions (IDE), a
sponsor must notify the FDA and all reviewing IRBs of any unanticipated adverse device effect
(UADE). What is the mandatory reporting timeframe for the sponsor to submit this report after
first receiving notice of the effect?
A) Within 2 working days.
B) Within 5 working days.
,C) Within 10 working days.
D) Within 30 calendar days.
Correct Answer: C) Within 10 working days.
*Explanation: According to 21 CFR 812.150(b)(1), the sponsor must report the results of an
evaluation of an unanticipated adverse device effect to the FDA and all reviewing IRBs and
participating investigators within 10 working days after the sponsor first receives notice of the
effect. Distractor B (5 days) is the timeframe for the investigator to notify the sponsor, making it
a common point of confusion for regulatory professionals.
Question 3: A biotechnology firm is developing a new biologic. During clinical development,
they identify a change in the manufacturing process that significantly alters the impurity profile
of the final product. According to ICH Q5E, what is the primary regulatory concern?
A) The cost-effectiveness of the new manufacturing process.
B) The comparability of the product before and after the manufacturing change.
C) The marketing strategy for the biologic in the European Union.
D) The shelf-life stability of the original product lot.
Correct Answer: B) The comparability of the product before and after the manufacturing
change.
*Explanation: ICH Q5E provides guidance on "Comparability of Biotechnological/Biological
Products Subject to Changes in their Manufacturing Process." The primary concern is ensuring
that the product’s safety, purity, and potency remain unchanged after a process modification. If
the impurity profile shifts, the manufacturer must demonstrate through analytical testing and
potentially clinical studies that the new product is comparable to the original, as required by
regulatory agencies.
Question 4: Which of the following is considered "adulterated" under Section 501(f) of the
Federal Food, Drug, and Cosmetic (FD&C) Act?
A) A Class II device that was properly cleared via the 510(k) pathway but has a typo on its outer
box labeling.
B) A Class III device that is being sold in commercial distribution without an approved
Premarket Approval (PMA) application.
C) A pharmaceutical drug that was manufactured in a facility that has not been inspected by the
FDA in over five years.
, D) A medical device that is identical to a predicate but was marketed without a submission of
any kind.
Correct Answer: B) A Class III device that is being sold in commercial distribution without
an approved Premarket Approval (PMA) application.
*Explanation: Section 501(f) of the FD&C Act explicitly deems a device adulterated if it is a
class III device that is required to have an approved PMA and is being distributed without one.
Mislabeling (Distractor A) generally falls under "misbranded" rather than "adulterated" under
the Act. Distractor C relates to cGMP compliance, which is a different regulatory category, and
D is a broad generalization that lacks the specific statutory nexus defined in 501(f).
Question 5: A manufacturer is developing a Quality Management System (QMS) compliant with
ISO 13485:2016. Which element is mandatory for the "Design and Development" section?
A) A comprehensive analysis of the marketing budget.
B) A documented design and development plan.
C) A list of all competitors in the global market.
D) A signed guarantee of product profit.
Correct Answer: B) A documented design and development plan.
*Explanation: ISO 13485:2016 requires the organization to plan and control the design and
development of medical devices. This includes establishing a formal design and development
plan that outlines the design stages, the review, verification, and validation activities, and the
responsibilities for each task. The other options are business/commercial metrics, not
quality/regulatory requirements for design controls.
Question 6: In the European Union, under the Medical Device Regulation (MDR) 2017/745,
what is the primary role of the Notified Body?
A) To finalize the clinical trial design for all Class I devices.
B) To conduct conformity assessments for medical devices prior to CE marking.
C) To act as the official representative for the European Medicines Agency (EMA).
D) To handle the day-to-day manufacturing operations of the medical device firm.
Correct Answer: B) To conduct conformity assessments for medical devices prior to CE
marking.
Advanced Prep: Master Global & US
Regulatory Pathways & Compliance Practice
Questions
Subject: Healthcare Product Lifecycle & Global Regulatory Affairs
Question 1: A medical device manufacturer is preparing a 510(k) submission for a new
cardiovascular stent. Which of the following conditions, if present, would most likely lead to the
FDA determining that the device is "not substantially equivalent" (NSE)?
A) The device utilizes a new biocompatible coating never before used on an FDA-cleared stent.
B) The device is similar in intended use but uses a different sterilization method than the
predicate.
C) The device has a slightly different geometric profile that does not impact its performance
characteristics.
D) The clinical data provided shows the device performs identically to the predicate device.
Correct Answer: A) The device utilizes a new biocompatible coating never before used on an
FDA-cleared stent.
*Explanation: The 510(k) pathway is predicated on demonstrating substantial equivalence to a
legally marketed predicate device. While minor modifications in labeling or materials are often
acceptable, the introduction of a new technology—such as a novel biocompatible coating—
introduces new questions of safety and effectiveness that cannot be adequately addressed
through a 510(k) comparison, necessitating a Premarket Approval (PMA) or a De Novo
classification request. Distractors B and C describe modifications that are often manageable
within a 510(k) framework via supplemental performance data, and D describes a scenario that
strongly supports substantial equivalence.
Question 2: Under the 21 CFR 812 regulations for Investigational Device Exemptions (IDE), a
sponsor must notify the FDA and all reviewing IRBs of any unanticipated adverse device effect
(UADE). What is the mandatory reporting timeframe for the sponsor to submit this report after
first receiving notice of the effect?
A) Within 2 working days.
B) Within 5 working days.
,C) Within 10 working days.
D) Within 30 calendar days.
Correct Answer: C) Within 10 working days.
*Explanation: According to 21 CFR 812.150(b)(1), the sponsor must report the results of an
evaluation of an unanticipated adverse device effect to the FDA and all reviewing IRBs and
participating investigators within 10 working days after the sponsor first receives notice of the
effect. Distractor B (5 days) is the timeframe for the investigator to notify the sponsor, making it
a common point of confusion for regulatory professionals.
Question 3: A biotechnology firm is developing a new biologic. During clinical development,
they identify a change in the manufacturing process that significantly alters the impurity profile
of the final product. According to ICH Q5E, what is the primary regulatory concern?
A) The cost-effectiveness of the new manufacturing process.
B) The comparability of the product before and after the manufacturing change.
C) The marketing strategy for the biologic in the European Union.
D) The shelf-life stability of the original product lot.
Correct Answer: B) The comparability of the product before and after the manufacturing
change.
*Explanation: ICH Q5E provides guidance on "Comparability of Biotechnological/Biological
Products Subject to Changes in their Manufacturing Process." The primary concern is ensuring
that the product’s safety, purity, and potency remain unchanged after a process modification. If
the impurity profile shifts, the manufacturer must demonstrate through analytical testing and
potentially clinical studies that the new product is comparable to the original, as required by
regulatory agencies.
Question 4: Which of the following is considered "adulterated" under Section 501(f) of the
Federal Food, Drug, and Cosmetic (FD&C) Act?
A) A Class II device that was properly cleared via the 510(k) pathway but has a typo on its outer
box labeling.
B) A Class III device that is being sold in commercial distribution without an approved
Premarket Approval (PMA) application.
C) A pharmaceutical drug that was manufactured in a facility that has not been inspected by the
FDA in over five years.
, D) A medical device that is identical to a predicate but was marketed without a submission of
any kind.
Correct Answer: B) A Class III device that is being sold in commercial distribution without
an approved Premarket Approval (PMA) application.
*Explanation: Section 501(f) of the FD&C Act explicitly deems a device adulterated if it is a
class III device that is required to have an approved PMA and is being distributed without one.
Mislabeling (Distractor A) generally falls under "misbranded" rather than "adulterated" under
the Act. Distractor C relates to cGMP compliance, which is a different regulatory category, and
D is a broad generalization that lacks the specific statutory nexus defined in 501(f).
Question 5: A manufacturer is developing a Quality Management System (QMS) compliant with
ISO 13485:2016. Which element is mandatory for the "Design and Development" section?
A) A comprehensive analysis of the marketing budget.
B) A documented design and development plan.
C) A list of all competitors in the global market.
D) A signed guarantee of product profit.
Correct Answer: B) A documented design and development plan.
*Explanation: ISO 13485:2016 requires the organization to plan and control the design and
development of medical devices. This includes establishing a formal design and development
plan that outlines the design stages, the review, verification, and validation activities, and the
responsibilities for each task. The other options are business/commercial metrics, not
quality/regulatory requirements for design controls.
Question 6: In the European Union, under the Medical Device Regulation (MDR) 2017/745,
what is the primary role of the Notified Body?
A) To finalize the clinical trial design for all Class I devices.
B) To conduct conformity assessments for medical devices prior to CE marking.
C) To act as the official representative for the European Medicines Agency (EMA).
D) To handle the day-to-day manufacturing operations of the medical device firm.
Correct Answer: B) To conduct conformity assessments for medical devices prior to CE
marking.
